Integrating patient iPSC -derived brain organoid disease models with cutting-edge computational tools of deep-learning and network medicine to transform CNS drug discovery.
Discovering and developing breakthrough medicines for complex neurological diseases.
Precision medicine approach
Genetically validated targets that drive human disease biology.
BrainStorm is led by an experienced team of neuroscientists, stem cell biologists, and drug developers.
We de-risk clinical translation using patient biology, biomarker-based screening, and advanced data analytics.
Leveraging deep learning and network medicine.
To discover and develop breakthrough medicines for complex neurological disorders by integrating patient-derived iPSC models of brain disease, biomarker-based screening, and the computational tools of deep learning and network medicine to drive successful clinical outcomes faster at a reduced cost.
BrainStorm is led by an experienced team of drug hunters, neuroscientists, and stem cell biologists with a shared strategic vision to transform CNS drug discovery by leveraging a robust discovery engine combining human biology with the power of machine learning.
Dr. Robert Fremeau
Founder and CSO
Experienced R&D leader with 20+ years experience in academia and industry.
Dr. Alysson Muotri
Stem cell and brain organoid pioneer
Created the first human organoid models for neurodevelopmental disorders.
Dr. James Treanor
Experienced Biotech C-Suite Officer
Current BOD, SAB member, and former CEO at ADRx, Inc.
Dr. Mark H. Norman
Innovative medicinal chemist
30+ years of drug discovery and development experience.
Dr. Edoarda Marcora
Computational biology, software development, and genetics expertise.
Professor of Genetics, Genomic Sciences, and Neuroscience, Mount Sinai Icahn School of Medicine; member of the Icahn Genomics Institute